Site Under Construction

Treatment of morphea with narrowband ultraviolet B- a case series-Final

Ma. Lorna F. Frez MD, FPDS, Kathleen May V. Eusebio-Alpapara MD, DPDS, Georgina C. Pastorfide MD, FPDS, Rochelle L. Castillo MD and Giselle S. Tioleco-Ver MD, FPDS



Morphea, is a rare autoimmune disease presenting with fibrotic changes in the dermis and subcutis. It is a benign condition associated with significant atrophy and sclerosis leading to disfigurement, flexure contractures, and impaired function. Ultraviolet A1 and photochemotherapy are highly effective treatment options but are not readily available in the country. Narrowband ultraviolet B (NBUVB), on the other hand, is readily available, affordable, and safe to use.



Three patients diagnosed with different variants of morphea (bilateral generalize morphea, unilateral generalized morphea, and circumscribed morphea). underwent 30 sessions of NBUVB. Treatment response was assessed using tightness and itch Visual Analogue Scale (VAS), Modified Skin Score (MSS), photographic comparison, ultrasonographic measurement, and histopathologic analysis. NBUVB treatment resulted to 14-60% decrease in the tightness and itch VAS. MSS was also reduced by 35-50%. The size, pigmentation, and erythema of the lesions also decreased. Ultrasonography showed an improvement in the thickness of lesions after treatment. Histopathologic study showed less packed collagen with increase in inter-bundle spaces.



Response to treatment was influenced by the age of the lesion and anatomical location. More chronic lesions tend to have less response. Lesions on the face exhibited the greatest improvement while lesions on the lower extremities had the least improvement. This is the first case series study in the country that uses NBUVB as treatment for morphea. The improvement of the sclerotic and atrophic lesions treated with narrowband UVB treatment may be an acceptable substitute for UVA1 and PUVA.


  1. Martin R and Kamran G. Morphea and Lichen Sclerosus. In: Bolognia, JL , Jorizzo JL and Schaffer, JV (editors). Dermatology. 3rd ed. New York:
    Elsevier. 2012. Vol 1.p 657-669
  2. Badea,I. Taylor, M., Rosenberg, A., Folvari, M. Pathogenesis and Therapeutic Approaches for Improved Topical Treatment in Localized Scleroderma and Systemic Sclerosis. Rheumatology (Oxford).2009 Mar;48(3):213-21
  3. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE . The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24(1):73.
  4. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385.
  5. Knobler R, Moinzadeh P, Hunzelmann N , Kreuter A, Cozzio A, Mouthon L, European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. JEADV 2017, 31, 1401–1424.
  6. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT .Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545.
  7. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T.A randomized controlled study of low-dose UVA1, medium-dose UVA1 and narrow-band UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006 Mar;54(3):440-7. Epub 2006 Jan 30.
  8. Buense,R, Duarte I.A, Bouer, M. Localized scleroderma: assessment of the therapeutic response to phototherapy. An Bras Dermatol. 2012 Jan- Feb;87(1):63-9.
  9. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of Disease Damage: a proof-to-concept study. Rheumatology (Oxford). 2010 Feb;49(2):373-81
  10. Weichenthal M. and Schwarz T. Phototherapy: How does UV work?. Photodermatol Photoimmunol Photomed. 2005 Oct;21(5):260-6.
  11. Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HW, Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. Journal of Investigative Dermatology. 1991.Vol 97: 667-7
  12. Teske NM and Jacobe HT. Morphea (Localized scleroderma). In: Varga, J., Denton, C.P., Wigley, F.M., Allanore, Y., Kuwana, M. (editors). Scleroderma From Pathogenesis to Comprehensive Management. New York: Springer International Publishing. 2017.pp 94-102

REquesting Permission

Treatment of morphea with narrowband ultraviolet B- a case series-Final